Chipscreen Biosciences, Ltd.

Shanghai, Shanghai Municipality

OncologyGrant-only

What changed

Phase II trial registered: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

2mo agoTrial registeredApr 20, 2026Source filing (opens the source filing in a new tab)

Momentum

64no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R35 · $841k · non-dilutive
Jun 5, 2023
UNIVERSITY OF CALIFORNIA RIVERSIDE · PI ZHOU, CHANGCHENG · NIEHS · award ends Mar 31, 2031 · Role of PXR in EDC-induced cardiovascular disease
NIH RePORTER · NIH RePORTER 11074560 (opens the source filing in a new tab)
Trial
PHASE2 registered
Oct 26, 2022
Non Small Cell Lung Cancer · COMPLETED · sponsor: Chipscreen Biosciences, Ltd. · A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
ClinicalTrials.gov · NCT05519865 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.24{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
2mo agoTrial completedSource (opens the source filing in a new tab)
NIH R35 · $0.8M · Role of PXR in EDC-induced cardiovascular disease
Mar 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R35 · $841k · non-dilutive

PHASE2 registered